title: A comparison of standard and high-dose regimens for the initiation of amiodarone therapy.
abstract: The effects of two regimens for the initiation of amiodarone therapy were compared in 92 patients with inducible sustained ventricular tachycardia (VT) at baseline electrophysiologic testing. Two groups of 46 patients each received a total of 16.8 gm of oral amiodarone before follow-up electrophysiologic testing. Group A (standard dose) received 1200 mg/day for 14 days, and group B (high dose) received 2400 mg/day for 7 days. Amiodarone suppressed the induction of sustained VT in six subjects (13%) in group A versus 10 (22%) in group B (p = NS). In subjects who continued to have inducible VT after amiodarone loading, the mean increase in cycle length of induced VT was similar in group A (delta = 85 +/- 73 msec) and group B (delta = 78 +/- 59 msec). The mean increase in sinus cycle length, AH and HV intervals, paced QRS duration, and ventricular refractory periods was also not significantly different between the two groups. Side effects developed in 10 (22%) patients in group B but were serious only in one, and one patient required a reduction in dosage. Thus compared to the 14-day standard-dose regimen, the 7-day high-dose regimen was well tolerated and had similar effects on VT inducibility and electrophysiologic variables. Its use may significantly shorten the duration of hospitalization in patients with life-threatening inducible VT who are undergoing loading with amiodarone on an inpatient basis.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
authors.forename: J
authors.initials: J
authors.lastname: Summitt
authors.forename: F
authors.initials: F
authors.lastname: Morady
authors.forename: A
authors.initials: A
authors.lastname: Kadish
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage* / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D004334:Drug Administration Schedule; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013575:Syncope / Q000188:drug therapy; D013610:Tachycardia / Q000175:diagnosis / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000638:Amiodarone